ข่าวประชาสัมพันธ์ Cardiovascular Disease+Neuome Peptides

Possible Breakthrough in Cardiovascular Disease Diagnostics for Southeast Asia

Neuome Peptides Pte. Ltd., a Singapore-based company has established an assay-development platform , powered by machine learning and novel, patented algorithms for the quantifiable detection of biomarkers. The company successfully designed specific peptides to bind to pre-established, proven biomarkers for Cardiovascular Diseases and is currently developing effective diagnostic assays . The use of small peptides, conjugated with gold nanoparticles, allows a balance of high specificity and

นูโอม เปปไทด์ส (Neuome Peptides Pte. Ltd.... ความก้าวหน้าที่มีศักยภาพวินิจฉัยโรคหัวใจและหลอดเลือดสำหรับเอเชียตะวันออกเฉียงใต้ — นูโอม เปปไทด์ส (Neuome Peptides Pte. Ltd.) บริษัทสัญชาติสิงคโปร์ ได้คิด...

โรคเบาหวานเสี่ยงโรคหลอดเลือดหัวใจ (Cardio... เบาหวานเสี่ยงต่อโรคหัวใจอย่างไร — โรคเบาหวานเสี่ยงโรคหลอดเลือดหัวใจ (Cardiovascular Disease and Diabetes) ร้อยละ 68 ของผู้ป่วยเบาหวาน อายุ 65 ปีขึ้นไปจะ...

International Diabetes Federation (IDF) Global Survey Reveals 2 in 3 People With Type 2 Diabetes Have Cardiovascular Disease Risk Factors and/or Have Experienced a Cardiovascular Event

- Cardiovascular disease (CVD) is the leading cause of disability and death in people with type 2 diabetes[1] -...

World Heart Day: Nearly One in Five Deaths From Cardiovascular Disease are Caused by Air Pollution, a Total of 3 Million Deaths Globally Every Year

- On World Heart Day (WHD), 29 September 2018, World Heart Federation (WHF) is raising awareness of the link between poor air quality and cardiovascular...

IDF and Novo Nordisk Launch First-ever Global Survey on Cardiovascular Disease Awareness among People with Type 2 Diabetes

- Taking Diabetes to Heart is a global online survey for people with type 2 diabetes to gain important insights about their awareness of cardiovascular disease (CVD) Globally,...

Resverlogix Completes Dosing In ASSURE Clinical Trial

IVUS data will evaluate plaque regression in patients with high-risk Cardiovascular Disease TSX Exchange Symbol: RVX Resverlogix Corp. (TSX:RVX) today announced that it has completed dosing in ASSURE, a Phase 2b clinical trial evaluating RVX-208,...

Photo Release: KTC members make donation for children with congenital heart defect.

Mr. Dusit Ratchatasetanant(right), Executive Vice President Human Resources, “KTC” or Krungthai Card Public Company Limited, presented 80,441.50 Baht donation collected through the boxes at KTC Touch customer service...

Resverlogix's BET Protein Inhibitor RVX-208 Meets Primary Endpoint in SUSTAIN Clinical Trial in Patients With High Risk Cardiovascular Disease

Significant Increase in Functional HDL Persisted Throughout the 24-week Study Period Results from ASSURE Study Expected H1 2013, Using IVUS to Measure...

ASIANET: Worldwide Study to Evaluate New Approach

Worldwide Study to Evaluate New Approach to Preventing Cardiovascular Disease in Ace Inhibitor-Intolerant Patients - Largest Cardiovascular Protection Trial Ever Conducted in This Patient Population Will Parallel Landmark 'ONTARGET' Study - MILAN,...

ASIANET: Landmark Worldwide 'ONTARGET' Study of Approximately 28,000 Patients

Landmark Worldwide 'ONTARGET' Study of Approximately 28,000 Patients to Evaluate the Role of a New Therapeutic Approach In Prevention Of Cardiovascular Disease Study at Up to 700 Sites Will Build On Landmark Hope Trial...